A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors.

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

Collaborating with a local Destination Marketing Organization (DMO) for your next event can significantly expand your reach. Cities such as St. Louis Park and Golden Valley have DMOs that offer ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Amyloidosis is an underdiagnosed, progressive group of diseases characterized by the abnormal buildup of a protein called amyloid in organs and tissues throughout the body. Jonathan Dotson, founder of ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Learn how ATTR-CM is diagnosed, common warning signs, and why early detection is important to healthy outcomes.

Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL ...